Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Retrieved on: 2025-08-28 23:46:55

Tags for this article:

Click the tags to see associated articles and topics

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug. View article details on hiswai:

Excerpt

In its key trial comparing ONS-5010 to Roche's Lucentis, the therapy did not demonstrate equivalent performance at the eight-week mark. That ...

Article found on: www.tradingview.com